Key Findings: 
Type of Study: 
Study Result:  Inconclusive
Research Location(s): 
Year of Pub: 
Cannabinoids Studied: 
Chemotype: 
Terpenes Studied: 
Receptors Studied: 
Ligands Studied: 
DOSING DETAILS   
Study Dosing Objective:  Effective Dose, Safety Profile,
Established Protocol:  Effective dose with adverse effects
Route of Administration: 
Cannabinoid Ratio:  (CBD : Pharma CBD)   0 : 0    
Dosage Form:  cannabidiol or Epidiolex
Maximum Dose:  20 mg/kg body mass/d
Adverse Events:  CBD is not associated with major safety risks: changes in somnolence, decreased appetite, diarrhea, hormone changes, decreased fertility, and hepatic impairment at higher dosing.
Citation: